Lilly Spends $2.3 Billion on Something That Isn't a GLP-1 [Yahoo! Finance]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
Eli Lilly announced Monday it would acquire Ajax Therapeutics, a privately held blood cancer specialist, for up to $2.3 billion in cash. In the current pharmaceutical zeitgeist, that almost qualifies as an act of genuine contrarianism. To understand why, consider what Lilly has become: the GLP-1 company. Tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity, has turned Lilly into one of the most valuable companies on earth, the kind of stock that gets mentioned at dinner parties by people who don't usually talk about stocks. The entire pharma industry has spent the last two years scrambling into the weight-loss drug business, throwing billions at GLP-1 pipelines like it's 2021 and the asset class is SPACs. Lilly, flush with cash and apparently feeling adventurous, is going a different direction and doing something cute like curing cancer. Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Eli Lilly and Company (LLY) had its price target lowered by Leerink Partners from $1,296.00 to $1,058.00. They now have an "outperform" rating on the stock.MarketBeat
- Lilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera [Yahoo! Finance]Yahoo! Finance
- Lilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera [TheStreet.com]TheStreet.com
- Lilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia veraPR Newswire
- Eli Lilly and Company's (LLY) Foundayo Gets Prescribed 3,707 Times in the US in Second Week of Launch, Reuters Reports [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 2/4/26 - Beat
LLY
Sec Filings
- 4/21/26 - Form 4
- 4/21/26 - Form 4
- 4/21/26 - Form 4
- LLY's page on the SEC website